Hauser's FDA Rx: The FDA needs an NTSB

Sun, 03/10/2013 - 10:25pm
Mass Device

Post-approval medical device and pharmaceutical surveillance duties should be taken away from the FDA, says long-time patient safety advocate and FDA critic Dr. Robert Hauser, who's advocating for an independent bureau akin to the National Transportation Safety Board.

Dr. Robert Hauser

Dr. Robert Hauser hopes to push a major change at the FDA, looking to shift the monitoring of medical devices and drugs that are already on the market from the FDA to an independent entity.

Hauser, a long-time patient safety advocate and vocal FDA critic, is aiming to sell Capitol Hill on a new structure for the U.S. healthcare regulation system akin to how the nation deals with transportation safety, he told in an exclusive interview.

"We need an independent organization to look at major adverse events associated with drugs and devices, separate from the FDA and which has no regulatory authority, whose only job is to investigate and then report their findings," Hauser told us today during the American College of Cardiology conference in San Francisco. "I'm interested in making a safer device or drug for a patient. I'm going to recruit a couple people and go to Congress."



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.